Related Experiment Video

Updated: Jan 6, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K

Small Molecule Inhibition of Glycogen Synthase Kinase-3 in Cancer Immunotherapy

Alison Taylor1, Christopher E Rudd2

  • 1Division of Haematology and Immunology, Leeds Institute of Medical Research, Leeds, UK.

Advances in Experimental Medicine and Biology
|October 3, 2019
PubMed

Insights

Glycogen synthase kinase-3 (GSK-3) regulates PD-1 in T-cells, offering a new target for cancer immunotherapy. Small molecule inhibitors targeting GSK-3 show promise in eliminating tumors, similar to current treatments.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Immune checkpoint blockade (ICB) is a successful cancer immunotherapy, but many patients and cold tumors remain unresponsive.
  • Novel therapeutic strategies are needed to enhance immunotherapy efficacy.

Purpose of the Study:

  • To investigate the role of glycogen synthase kinase-3 (GSK-3) in regulating PD-1 expression in T-cells.
  • To explore the potential of small molecule inhibitors (SMIs) targeting GSK-3 for cancer immunotherapy.

Main Methods:

  • Investigated GSK-3 as a regulator of PD-1 in T-cells.
  • Utilized small molecule inhibitors (SMIs) to target GSK-3.
  • Evaluated the efficacy of GSK-3 SMIs in preclinical melanoma mouse models.

Main Results:

  • GSK-3 was identified as a central regulator of PD-1 in T-cells.
  • GSK-3 SMIs demonstrated efficacy comparable to anti-PD-1 therapy in eliminating melanoma.
  • Down-regulation of PD-1 via GSK-3 inhibition is a viable immunotherapeutic strategy.

Conclusions:

  • Targeting GSK-3 with SMIs represents a promising novel approach for cancer immunotherapy.
  • Further development of SMIs targeting co-receptors like GSK-3 could improve patient outcomes in immunotherapy.
Keywords:
Glycogen synthase kinase-3ImmunotherapyPD-1T-cells

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.7K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540